Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
0.00 | -353.00K | -296.00K | -140.00K | -47.00K | EBIT |
-104.18M | -79.94M | -58.93M | -26.29M | -9.30M | EBITDA |
-104.18M | -79.59M | -58.63M | -26.15M | -9.25M | Net Income Common Stockholders |
-86.48M | -69.13M | -51.72M | -26.14M | -9.31M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
341.44M | 203.47M | 251.21M | 302.18M | 15.22M | Total Assets |
363.56M | 225.86M | 266.18M | 306.70M | 16.01M | Total Debt |
6.22M | 6.50M | 2.62M | 1.18M | 142.00K | Net Debt |
-85.74M | -51.51M | -248.59M | -301.00M | -15.08M | Total Liabilities |
20.41M | 21.59M | 8.35M | 4.96M | 29.65M | Stockholders Equity |
343.15M | 204.26M | -95.70M | 301.74M | -13.64M |
Cash Flow | Free Cash Flow | |||
-70.44M | -50.91M | -50.84M | -24.41M | -8.07M | Operating Cash Flow |
-69.77M | -50.14M | -50.28M | -23.75M | -7.76M | Investing Cash Flow |
-98.40M | -144.60M | -559.00K | -645.00K | -312.00K | Financing Cash Flow |
202.14M | 1.54M | 632.00 | 311.35M | 23.43M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $3.05B | ― | -214.50% | ― | 29.01% | 23.93% | |
52 Neutral | $5.22B | ― | -31.26% | ― | 104.04% | 87.80% | |
48 Neutral | $6.36B | 1.09 | -49.92% | 2.63% | 17.17% | 0.95% | |
45 Neutral | $475.65M | ― | -42.91% | ― | ― | 2.90% | |
42 Neutral | $86.28M | ― | -54.21% | ― | -78.55% | -0.92% | |
34 Underperform | $410.92M | ― | -31.60% | ― | ― | 6.72% | |
29 Underperform | $67.55M | ― | -155.76% | ― | 25.77% | 32.56% |
Tyra Biosciences announced changes in its Board of Directors on January 28, 2025, with the resignation of Nina Kjellson and the appointment of Adele M. Gulfo. Gulfo brings extensive experience from her roles in major pharmaceutical companies like Sumitomo Pharma America, Mylan, and Pfizer. Her appointment is expected to strengthen Tyra Biosciences’ strategic direction, given her background in commercial and business development in the biopharmaceutical industry. With her appointment, Gulfo will also receive stock options and cash compensation under the company’s director compensation program.